LB PHARMACEUTICALS INC (LBRX) stock intrinsic value fair value estimate & owner earnings analysis

LB Pharmaceuticals is a clinical-stage drug developer that listed on Nasdaq in September 2025. It has no products for sale and no revenue. Its only late-stage asset is LB-102, an oral once-daily drug for schizophrenia. The company began a six-week Phase 3 trial (called NOVA-2) in March 2026 and says it expects to report topline results in the second half of 2027. How we valued it. A business that is losing money has negative owner earnings, so there is no earnings stream to discount. In 2025 the company's cash used in operations was $35.2 million and stock-based pay was $4.2 million, which puts owner earnings at roughly negative $25.8 million (negative $3.20 per weighted average share, a figure distorted by the September 2025 listing). In 2024 the loss was larger, at roughly negative $60.2 million. The company's spending is now rising. In the first half of 2026, cash used in operations was $60.9 million and stock-based pay was $7.5 million, and second-quarter research spending alone was $44.1 million as the Phase 3 trial ramped up. Because we credit only what has already happened or is contractually locked in, we give LB-102 no value for the chance the trial succeeds and the drug is approved: no trial result is in hand, no approval exists, and the company has no product sales. What remains is the cash the company holds, less what it will spend before the trial answers the question. We discount that spending at 6% a year. We do not deduct debt, as the company carries very little (total liabilities were $11.6 million at year-end 2025). Starting point. At June 30, 2026 the company held $324.9 million of cash and marketable securities. That includes about $100 million (before costs) raised in a February 2026 private placement at $21.17 a share. We divide by about 30.1 million shares: 28.7 million outstanding at June 30, 2026, plus 1.4 million pre-funded warrants issued in that placement. This count leaves out stock options and other employee awards. In its March 2026 annual report, management said its cash, including the private placement, should last into the second quarter of 2029 based on its plans at that time. Bear case: $1.26 a share. The second-quarter pace of spending continues. That quarter's net loss of $51.6 million equals roughly $200 million a year. The trial reports at the end of 2027, 18 months after June 2026, and the company then stops with nothing further to build on. About $287 million (present value) is spent, leaving about $38 million, or $1.26 a share. Base case: $2.69 a share. Spending runs at about $170 million a year, roughly midway between the first-half 2026 average of about $137 million and the second-quarter pace. The trial again reports at the end of 2027. About $244 million (present value) is spent, leaving about $81 million, or $2.69 a share. Bull case: $6.38 a share. Spending holds at the first-half 2026 average of about $137 million a year, and results arrive at the start of the second half of 2027, 12 months after June 2026, in line with the company's own guidance. About $133 million (present value) is spent, leaving about $192 million, or $6.38 a share. What we left out. We give no credit for a positive Phase 3 result, an FDA approval, or future sales. A success would be worth far more than these figures, but it has not happened, so it is not in the numbers. The company also owes holders of royalty certificates up to 2.75% of worldwide net sales of LB-102 through 2035 and up to 3.25% afterwards. This would reduce the value of any future sales, but it costs nothing until sales begin. The company may also need to raise more money if the trial runs long or the drug needs additional studies. That would dilute today's shareholders and is not included. What would make this wrong. If the company can stretch its spending well below $137 million a year, or if the trial succeeds and leads to an approval, the shares are worth more than our base case. If the trial is delayed or costs more than the second-quarter pace, they are worth less. We could not fully reconcile the jump in second-quarter research costs from the stored filings alone, so we treated it as a high-end range rather than the base. Margin-of-safety price: $1.00. A pre-revenue drug developer with a single late-stage asset and a spending rate that is still rising needs a very large margin of safety, so the margin-of-safety price is set at a level the cash-based bear case covers.